464.93 USD
-7.06 (-1.5%)
464.93 USD
0 (0%)
Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 525 industry peers in the Biotechnology industry. UTHR scores excellent points on both the profitability and health parts. This is a solid base for a good stock. UTHR has a decent growth rate and is not valued too expensively. These ratings could make UTHR a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
- UTHR had positive earnings in the past year.
- UTHR had a positive operating cash flow in the past year.
- UTHR had positive earnings in each of the past 5 years.
- Each year in the past 5 years UTHR had a positive operating cash flow.
1.2 Ratios
- UTHR's Return On Assets of 17.30% is amongst the best of the industry. UTHR outperforms 95.85% of its industry peers.
- The Return On Equity of UTHR (19.30%) is better than 95.66% of its industry peers.
- With an excellent Return On Invested Capital value of 17.33%, UTHR belongs to the best of the industry, outperforming 96.98% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for UTHR is below the industry average of 18.07%.
- The last Return On Invested Capital (17.33%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
- The Profit Margin of UTHR (40.65%) is better than 96.79% of its industry peers.
- In the last couple of years the Profit Margin of UTHR has grown nicely.
- UTHR has a Operating Margin of 48.65%. This is amongst the best in the industry. UTHR outperforms 99.43% of its industry peers.
- UTHR's Operating Margin has improved in the last couple of years.
- The Gross Margin of UTHR (88.59%) is better than 90.38% of its industry peers.
- In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so UTHR is creating value.
- UTHR has less shares outstanding than it did 1 year ago.
- UTHR has more shares outstanding than it did 5 years ago.
- UTHR has a better debt/assets ratio than last year.
2.2 Solvency
- UTHR has an Altman-Z score of 18.94. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
- UTHR has a Altman-Z score of 18.94. This is amongst the best in the industry. UTHR outperforms 88.30% of its industry peers.
- There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 18.94 |
ROIC/WACC1.96
WACC8.82%
2.3 Liquidity
- UTHR has a Current Ratio of 6.40. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 6.40, UTHR is doing good in the industry, outperforming 65.66% of the companies in the same industry.
- A Quick Ratio of 6.07 indicates that UTHR has no problem at all paying its short term obligations.
- UTHR has a better Quick ratio (6.07) than 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 15.90% over the past year.
- The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
- The Revenue has grown by 13.50% in the past year. This is quite good.
- Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
- Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
- UTHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue Next Year11.53%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 17.62 indicates a rather expensive valuation of UTHR.
- 94.91% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
- UTHR is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- UTHR is valuated correctly with a Price/Forward Earnings ratio of 15.63.
- Based on the Price/Forward Earnings ratio, UTHR is valued cheaply inside the industry as 95.28% of the companies are valued more expensively.
- UTHR's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.62 | ||
| Fwd PE | 15.63 |
4.2 Price Multiples
- 97.17% of the companies in the same industry are more expensive than UTHR, based on the Enterprise Value to EBITDA ratio.
- UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 95.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.93 | ||
| EV/EBITDA | 9.86 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.44
PEG (5Y)1.04
EPS Next 2Y9.98%
EPS Next 3Y8.48%
5. Dividend
5.1 Amount
- No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
464.93
-7.06 (-1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners98.84%
Inst Owner Change0.08%
Ins Owners1.84%
Ins Owner Change2.26%
Market Cap20.02B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target539.75 (16.09%)
Short Float %4.99%
Short Ratio4.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)3.77%
PT rev (3m)10.2%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)2.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.63%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)1.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.62 | ||
| Fwd PE | 15.63 | ||
| P/S | 6.4 | ||
| P/FCF | 17.93 | ||
| P/OCF | 12.86 | ||
| P/B | 3.04 | ||
| P/tB | 3.09 | ||
| EV/EBITDA | 9.86 |
EPS(TTM)26.39
EY5.68%
EPS(NY)29.75
Fwd EY6.4%
FCF(TTM)25.93
FCFY5.58%
OCF(TTM)36.14
OCFY7.77%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.44
PEG (5Y)1.04
Graham Number301.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 18.94 |
F-Score8
WACC8.82%
ROIC/WACC1.96
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.53%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year20.27%
EBIT Next 3Y4.67%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?
ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.
Can you provide the profitability details for UNITED THERAPEUTICS CORP?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
What are the PE and PB ratios of UNITED THERAPEUTICS CORP (UTHR) stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 17.62 and the Price/Book (PB) ratio is 3.04.
What is the expected EPS growth for UNITED THERAPEUTICS CORP (UTHR) stock?
The Earnings per Share (EPS) of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 12.23% in the next year.